A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
Six scientists at Columbia have received NIH “High-Risk” grants that support exceptionally creative scientists and unconventional approaches to solving major challenges in medicine.
The grant to the Vagelos College of Physicians and Surgeons will help medical researchers speed the application of scientific discoveries, so that new treatments can be delivered to patients faster.
Wang received the prize, awarded annually to immigrants whose work demonstrates exceptional insight or innovation, for his development of synthetic biology tools.
With $10 million from Pfizer, the Initiative aims to increase the participation of underrepresented minorities in clinical trials and enhance the diversity of clinical researchers.
Researchers at Columbia University Vagelos College of Physicians and Surgeons are leading the first U.S. trial of an experimental vaccine designed to treat an opioid use disorder.
A new preclinical study provides the first direct evidence that loss of a placental hormone during pregnancy alters long-term brain development, causing autism-like behaviors in male offspring.
Keith Diaz, May Hua, Jennifer Woo Baidal, and Hanrui Zhang will receive funding over the next three years to support their clinical and translational research.